242 related articles for article (PubMed ID: 26074046)
1. The Current Role of Liraglutide in the Pharmacotherapy of Obesity.
Christou GA; Katsiki N; Kiortsis DN
Curr Vasc Pharmacol; 2016; 14(2):201-7. PubMed ID: 26074046
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of the naltrexone/bupropion combination for the treatment of obesity: an update.
Christou GA; Kiortsis DN
Hormones (Athens); 2015; 14(3):370-5. PubMed ID: 26188223
[TBL] [Abstract][Full Text] [Related]
3. Liraglutide: A New Option for the Treatment of Obesity.
Nuffer WA; Trujillo JM
Pharmacotherapy; 2015 Oct; 35(10):926-34. PubMed ID: 26497479
[TBL] [Abstract][Full Text] [Related]
4. Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti-obesity therapies.
Farr OM; Upadhyay J; Rutagengwa C; DiPrisco B; Ranta Z; Adra A; Bapatla N; Douglas VP; Douglas KAA; Nolen-Doerr E; Mathew H; Mantzoros CS
Diabetes Obes Metab; 2019 Nov; 21(11):2459-2464. PubMed ID: 31282006
[TBL] [Abstract][Full Text] [Related]
5. liraglutide (SAXENDA⁰) and obesit. Still no satisfactory weight loss drugs.
Prescrire Int; 2016 Jan; 25(167):5-8. PubMed ID: 26942248
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacotherapy for obesity].
Bruun JM
Ugeskr Laeger; 2016 Oct; 178(44):. PubMed ID: 27808050
[TBL] [Abstract][Full Text] [Related]
7. Effects of Liraglutide and Behavioral Weight Loss on Food Cravings, Eating Behaviors, and Eating Disorder Psychopathology.
Chao AM; Wadden TA; Walsh OA; Gruber KA; Alamuddin N; Berkowitz RI; Tronieri JS
Obesity (Silver Spring); 2019 Dec; 27(12):2005-2010. PubMed ID: 31746553
[TBL] [Abstract][Full Text] [Related]
8. Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial.
Wadden TA; Tronieri JS; Sugimoto D; Lund MT; Auerbach P; Jensen C; Rubino D
Obesity (Silver Spring); 2020 Mar; 28(3):529-536. PubMed ID: 32090517
[TBL] [Abstract][Full Text] [Related]
9. Liraglutide for Type 2 diabetes and obesity: a 2015 update.
Iepsen EW; Torekov SS; Holst JJ
Expert Rev Cardiovasc Ther; 2015; 13(7):753-67. PubMed ID: 26106933
[TBL] [Abstract][Full Text] [Related]
10. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
[TBL] [Abstract][Full Text] [Related]
11. Pharmacotherapy for obesity in individuals with type 2 diabetes.
Chukir T; Shukla AP; Saunders KH; Aronne LJ
Expert Opin Pharmacother; 2018 Feb; 19(3):223-231. PubMed ID: 29376439
[TBL] [Abstract][Full Text] [Related]
12. Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: A pilot randomized trial.
Khoo J; Hsiang J; Taneja R; Law NM; Ang TL
Diabetes Obes Metab; 2017 Dec; 19(12):1814-1817. PubMed ID: 28503750
[TBL] [Abstract][Full Text] [Related]
13. A review of the metabolic effects of controlled-release Phentermine/Topiramate.
Kiortsis DN
Hormones (Athens); 2013; 12(4):507-16. PubMed ID: 24457398
[TBL] [Abstract][Full Text] [Related]
14. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.
Halawi H; Khemani D; Eckert D; O'Neill J; Kadouh H; Grothe K; Clark MM; Burton DD; Vella A; Acosta A; Zinsmeister AR; Camilleri M
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):890-899. PubMed ID: 28958851
[TBL] [Abstract][Full Text] [Related]
15. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome.
Jensterle M; Kravos NA; Pfeifer M; Kocjan T; Janez A
Hormones (Athens); 2015; 14(1):81-90. PubMed ID: 25885106
[TBL] [Abstract][Full Text] [Related]
16. Liraglutide: a review of its use in the management of obesity.
Scott LJ
Drugs; 2015 May; 75(8):899-910. PubMed ID: 25985864
[TBL] [Abstract][Full Text] [Related]
17. Current pharmacotherapy for obesity.
Srivastava G; Apovian CM
Nat Rev Endocrinol; 2018 Jan; 14(1):12-24. PubMed ID: 29027993
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial.
Papamargaritis D; Al-Najim W; Lim J; Crane J; Lean M; le Roux C; McGowan B; O'Shea D; Webb D; Wilding J; Davies MJ
BMJ Open; 2020 Feb; 10(2):e034137. PubMed ID: 32060156
[TBL] [Abstract][Full Text] [Related]
19. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.
Astrup A; Rössner S; Van Gaal L; Rissanen A; Niskanen L; Al Hakim M; Madsen J; Rasmussen MF; Lean ME;
Lancet; 2009 Nov; 374(9701):1606-16. PubMed ID: 19853906
[TBL] [Abstract][Full Text] [Related]
20. Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists.
Christensen RM; Juhl CR; Torekov SS
Drug Saf; 2019 Aug; 42(8):957-971. PubMed ID: 30972641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
